• Deracoxib’s Cytotoxic Impact on Canine Osteosarcoma Cells In

  2026-06-05

  This study rigorously compared the effects of deracoxib and piroxicam on canine osteosarcoma cell viability in vitro. The results demonstrated that deracoxib, a selective COX-2 inhibitor, reduced tumor cell viability at intermediate to high concentrations without affecting fibroblasts, although apoptosis was not induced under tested conditions. These findings inform the design of inflammation and cancer biology assays, highlighting deracoxib’s specificity and concentration-dependent efficacy.

• Strategic Calpain Inhibition: Translating Mechanism to Oncol

  2026-06-05

  Explore how Calpain Inhibitor II, ALLM empowers translational researchers to dissect calpain and cathepsin pathways in cancer, integrating mechanistic insights from lncRNA regulation in triple negative breast cancer with actionable guidance for apoptosis and protease inhibition assays in leukemia and lymphoma models.

• ARCA Cy5 EGFP mRNA (5-moUTP): Fluorescent mRNA for Delivery

  2026-06-04

  ARCA Cy5 EGFP mRNA (5-moUTP) is a 5-methoxyuridine modified, Cy5-labeled mRNA engineered for direct, high-fidelity detection of mRNA localization and translation efficiency in mammalian cells. Its dual fluorescent labeling enables robust tracking in microscopy and flow cytometry, while chemical modifications improve stability and suppress innate immune activation. This dossier reviews its mechanistic rationale, benchmarking evidence, and optimal application protocols.

• PTX3 Protects Against Steroid-Induced ONFH via TLR4/NF-κB/FG

  2026-06-04

  This study elucidates how pentraxin 3 (PTX3) mitigates glucocorticoid-induced osteonecrosis of the femoral head by modulating the TLR4/NF-κB/FGF21 signaling pathway. These findings highlight a mechanistic basis for targeting PTX3 and related pathways in bone preservation strategies under steroid exposure.

• EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Tracking Power

  2026-06-03

  Unlock simultaneous mRNA delivery visualization and protein expression quantification with EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP). This advanced reagent, supplied by APExBIO, elevates translation assays, immune suppression, and in vivo imaging through dual reporter capabilities and robust chemical modifications.

• Decoding Dual-Modality mRNA Tracking: Science Behind EZ Cap

  2026-06-03

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) revolutionizes gene delivery and intracellular tracking through advanced dual-modality detection. Discover the science, protocol insights, and practical implications for high-efficiency mRNA research.

• Sulfo-Cy5 Carboxylic Acid: Precision Fluorescent Dye for Lif

  2026-06-02

  Sulfo-Cy5 carboxylic acid is a hydrophilic, sulfonated fluorescent dye for life sciences, offering high water solubility and reduced fluorescence quenching. Its robust optical properties make it ideal for protein and peptide labeling in demanding imaging applications.

• Spatiotemporal mRNA Delivery: ARCA Cy5 EGFP mRNA (5-moUTP) i

  2026-06-02

  Explore how ARCA Cy5 EGFP mRNA (5-moUTP) enables precise, spatiotemporal mRNA delivery and localization analysis in mammalian cells. This article uniquely bridges cutting-edge delivery science with practical assay design, leveraging 5-methoxyuridine modified mRNA for enhanced translation efficiency.

• EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Tracking in mR

  2026-06-01

  EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) empowers researchers to simultaneously track mRNA delivery and monitor translation with unmatched sensitivity by combining Cy5 fluorescence and bioluminescence readouts. This dual-reporter construct, supplied by APExBIO, opens new horizons for optimizing transfection workflows and dissecting intracellular trafficking with quantitative precision.

• Epigenetic Regulation of PDK1 Drives TKI Resistance in Cance

  2026-06-01

  Recent research elucidates how epigenetic modifications by KDM3A and METTL16 upregulate PDK1, promoting resistance to EGFR-TKIs and facilitating cancer progression. These findings identify the KDM3A/METTL16/PDK1 pathway as a promising target for overcoming drug resistance and advancing programmed cell death research.

• KPT330 Enhances Cas9 Genome Editing Precision via mRNA Expor

  2026-05-31

  The referenced study demonstrates that KPT330, an FDA-approved SINE compound, improves the specificity of CRISPR-Cas9 genome and base editing by selectively inhibiting Cas9 mRNA nuclear export rather than directly inhibiting the Cas9 protein. This work introduces a new mechanism for modulating CRISPR-Cas9 activity, with important implications for minimizing off-target effects in gene editing applications.

• Genotyping Kit for Target Alleles: Streamlined DNA Prep for

  2026-05-30

  Accelerate your genetic workflows with the Genotyping Kit for target alleles of insects, tissues, fishes and cells, eliminating traditional extraction bottlenecks. This kit’s single-tube protocol, ready-to-use PCR mix, and robust contamination control empower high-throughput, reproducible analysis across diverse samples.

• Accelerating HepaRG Differentiation for HBV and HDV Infectio

  2026-05-29

  This study introduces a fast differentiation protocol for HepaRG cells, enabling efficient Hepatitis D virus (HDV) infection and providing a practical alternative to primary human hepatocytes for virology research. The findings clarify differences in hepatitis B virus (HBV) replication efficiency and establish a foundation for dissecting viral-host interactions in vitro.

• Cefiderocol Efficacy Against Drug-Resistant P. aeruginosa &

  2026-05-29

  Santerre Henriksen et al. performed a large-scale, multicenter surveillance study to evaluate the in vitro activity of cefiderocol versus contemporary β-lactam/β-lactamase inhibitor combinations against European Pseudomonas aeruginosa and Acinetobacter spp., including highly resistant clinical isolates. Their findings indicate that cefiderocol maintains potent activity against strains with limited therapeutic options, guiding future research and laboratory modeling of Gram-negative drug resistance.

• Phenothiazines Boost Macrophage Antibacterial Action via ROS

  2026-05-28

  The study demonstrates that phenothiazines, including dopamine D2 receptor inhibitors, enhance macrophage antibacterial activity by inducing reactive oxygen species and autophagy. This finding highlights a host-directed strategy against intracellular pathogens, providing a new perspective for combating antibiotic resistance.

11775 records 1/785 page Next 12345 下5页 Last page